购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

Axitinib

Rating icon 很棒
产品编号 T1452Cas号 319460-85-0
别名 阿昔替尼, 阿西替尼, AG-013736

Axitinib (AG-013736) 是一种多靶点酪氨酸激酶抑制剂,能够抑制 VEGFR1、VEGFR2、VEGFR3 和 PDGFRβ (IC50=4/20/0.4/2 nM)。Axitinib 具有抗肿瘤活性,用于肾细胞癌的治疗。

Axitinib
TargetMol

为众多的药物研发团队赋能,

让新药发现更简单!

Axitinib

Rating icon 很棒
纯度: 99.81%
产品编号 T1452 别名 阿昔替尼, 阿西替尼, AG-013736Cas号 319460-85-0

Axitinib (AG-013736) 是一种多靶点酪氨酸激酶抑制剂,能够抑制 VEGFR1、VEGFR2、VEGFR3 和 PDGFRβ (IC50=4/20/0.4/2 nM)。Axitinib 具有抗肿瘤活性,用于肾细胞癌的治疗。

规格价格库存数量
25 mg¥ 328现货
50 mg¥ 465现货
100 mg¥ 751现货
200 mg¥ 1,180现货
500 mg¥ 2,090现货
1 g¥ 3,330现货
1 mL x 10 mM (in DMSO)¥ 511现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"Axitinib"的相关化合物库

选择批次:
纯度:99.81%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
Axitinib (AG-013736) is a multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1, VEGFR2, VEGFR3, and PDGFRβ (IC50=4/20/0.4/2 nM). Axitinib has antitumor activity and is used in the treatment of renal cell carcinoma.
靶点活性
c-Kit:1.7 nM, VEGFR1/FLT1:0.1 nM, PDGFRβ:1.6 nM, VEGFR2/Flk1:0.18 nM, VEGFR2/KDR: 0.2 nM, VEGFR3: 0.1-0.3 nM
体外活性
方法:胶质瘤细胞 U87、T98 和 U251 用 Axitinib (0.1-100 µM) 处理 72 h,通过 MTT assay 测定细胞活力。
结果:治疗 72 h 后,Axitinib 抑制 U87 和 T98 细胞的生长,IC50 值分别为 12.7 µM 和 8.5 µM。相反,U251 细胞对 Axitinib 介导的细胞毒性作用更具抵抗力。[1]
方法:人上皮卵巢癌细胞 A2780、RMG1、HeyA8 和 HeyA8-MDR 用 Axitinib (1-4 µM) 处理 4 h,通过 Western Blot 检测靶点蛋白表达水平。
结果:不同剂量的 Axitinib 治疗以剂量依赖的方式显著降低了 A2780、RMG1 和 HeyA 8中磷酸化 EGFR2 的表达,但在 HeyA8 MDR 细胞中没有。[2]
体内活性
方法:为检测体内抗肿瘤活性,将 Axitinib (30 mg/kg,0.5% methyl cellulose) 口服给药给携带 A2780、RMG1 或 HeyA8 MDR 肿瘤的 BALB/c nude 小鼠,每天两次,持续 35-40 天。
结果:在 A2780 和 RMG1 模型中,Axitinib 治疗组的肿瘤重量与对照组相比显著降低了 50%,但在 HeyA8 MDR 模型中差异不显著。[2]
激酶实验
Porcine aorta endothelial (PAE) cells overexpressing full-length VEGFR-2, PDGFR-β, KIT, and NIH-3T3 overexpressing murine VEGFR-2 (Flk-1) or PDGFR-α were generated as described previously. The ELISA capture plates were prepared by coating 96-well ReactiBind plates with 100 μL/well of 2.5 μg/mL anti-VEGFR-2 antibody, 0.75 μg/mL anti-PDGFR-β antibody, 0.25 μg/mL anti-PDGFR-α antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody. Measurement of RTK phosphorylation by ELISA was done as described previously [1].
细胞实验
Endothelial or tumor cells were starved for 18 h in the presence of either 1% FBS (HUVEC) or 0.1% FBS (tumor cells). Axitinib was added and cells were incubated for 45 min at 37°C in the presence of 1 mmol/L Na3VO4. The appropriate growth factor was added to the cells, and after 5 min, cells were rinsed with cold PBS and lysed in the lysis buffer and a protease inhibitor cocktail. The lysates were incubated with immunoprecipitation antibodies for the intended proteins overnight at 4°C. Antibody complexes were conjugated to protein A beads and supernatants were separated by SDS-PAGE. The Super Signal West Dura kit was used to detect the chemiluminescent signal [1].
动物实验
AG-013736, a receptor kinase inhibitor of VEGFRs and, at higher doses, PDGFRs (IC50 = 0.1 nmol/L for VEGFR-1, 0.2 nmol/L for VEGFR-2, 0.1–0.3 nmol/L for VEGFR-3, and 1.6 nmol/L for PDGFRβ; ref. 18), was provided by Pfizer Global Research and given once daily by gavage in a volume of 0.13 mL. Control animals received 0.5% carboxymethylcellulose drug carrier. Irradiations were done on nonanesthetized mice using a 137Cs source operating at 2.4 Gy/min. Mice were confined to plastic jigs with tumor-bearing legs extended through an opening in the side, allowing local irradiations. Fractionated doses were given in five daily 2 Gy fractions per week (omitting weekends). For combination treatments, radiotherapy was delivered first, and AG-013736 was given within ~4 h. Mice were sacrificed, and tumors were excised and then quick frozen (using liquid nitrogen) following 1, 2, or 3 weeks of treatment [3].
别名阿昔替尼, 阿西替尼, AG-013736
化学信息
分子量386.47
分子式C22H18N4OS
CAS No.319460-85-0
SmilesC(=C/C1=CC=CC=N1)\C=2C=3C(=CC(SC4=C(C(NC)=O)C=CC=C4)=CC3)NN2
密度1.35 g/cm3
储存&溶解度
存储store at low temperature,keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: 9.7 mg/mL (25 mM)
溶液配制表
1mg5mg10mg50mg
1 mM2.5875 mL12.9376 mL25.8752 mL129.3761 mL
5 mM0.5175 mL2.5875 mL5.1750 mL25.8752 mL
10 mM0.2588 mL1.2938 mL2.5875 mL12.9376 mL
20 mM0.1294 mL0.6469 mL1.2938 mL6.4688 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy Axitinib | purchase Axitinib | Axitinib cost | order Axitinib | Axitinib chemical structure | Axitinib in vivo | Axitinib in vitro | Axitinib formula | Axitinib molecular weight